---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-241591"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2025-10-16T23:59:59+00:00"
generated_at: "2026-05-17T03:34:16.029913+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics raises $117M net in underwritten offering of stock and warrants

## Summary
- Offering includes 21.9M shares, pre-funded warrants for 28.7M shares, and Class A/B warrants for 50.6M shares each.
- Combined price per unit $2.47; net proceeds ~$117M, extending cash runway to end of 2028.
- If all warrants cash exercised, total net proceeds could reach $341.7M.
- Class A warrants expire on earlier of 30 days post Phase 1b data or 5 years; Class B warrants mandatory if stock >$6.66.
- Pre-funded warrants have $0.0001 exercise price and no expiration; all warrants subject to beneficial ownership limits.

## SEC filing metadata
- accession: 0001193125-25-241591
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2025-10-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000119312525241591/0001193125-25-241591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000119312525241591/d19436d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-241591
- JSON: https://secwatch.observer/filing/0001193125-25-241591.json
- Plain text: https://secwatch.observer/filing/0001193125-25-241591.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.